Acadia Pharmaceuticals
ACAD
228 hedge funds and large institutions have $3.61B invested in Acadia Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 52 funds opening new positions, 74 increasing their positions, 73 reducing their positions, and 34 closing their positions.
53% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 34
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
35% more call options, than puts
Call options by funds: $54.4M | Put options by funds: $40.3M
17% more capital invested
Capital invested by funds: $3.09B → $3.61B (+$516M)
7% more funds holding
Funds holding: 213 → 228 (+15)
1% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 73
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$71.2M |
| 2 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$31.9M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
+$28.7M |
| 4 |
SIG
Senator Investment Group
New York
|
+$26.8M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$40.5M |
| 2 |
O
OrbiMed
New York
|
-$39.2M |
| 3 |
State Street
Boston,
Massachusetts
|
-$36.4M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$34.2M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$29.3M |
ACAD Hedge Fund Activity: Q2 2016 in Review
228 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q2 2016, worth a combined $3.61B — up 17% from $3.09B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new ACAD positions and 34 closed out — a net gain of 18 holders — while 74 added to existing stakes and 73 trimmed.
The largest buyer was Lord, Abbett & Co, adding an estimated $71.2M. The largest seller was BlackRock Fund Advisors, cutting an estimated $40.5M.
- 228 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q2 2016, up from 213 in Q1 2016.
- Funds reported $3.61B of Acadia Pharmaceuticals stock for Q2 2016, up 17% quarter-over-quarter.
- 52 funds opened new Acadia Pharmaceuticals positions in Q2 2016 and 34 closed out, a net change of +18 holders.
- The largest Acadia Pharmaceuticals buyer in Q2 2016 was Lord, Abbett & Co, an estimated $71.2M added.
- The largest Acadia Pharmaceuticals seller in Q2 2016 was BlackRock Fund Advisors, an estimated $40.5M sold.
Based on aggregated 13F filings for Q2 2016.